Baret News – Lifestyle
Author:
One Call Corporation
ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
April 16, 2026
One Call Completes Acquisition of Data Dimensions, Establishing Foundational Infrastructure for the Healthcare Ecosystem
April 15, 2026
Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S.
April 9, 2026
FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
April 1, 2026
Phase 3b data presented at AAD Annual Meeting show Lilly’s Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
March 30, 2026
One Call to Acquire Data Dimensions, Transforming Care Coordination Across the Worker’s Compensation Ecosystem
March 4, 2026